Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis
V Di Lernia,1 F Bardazzi2 1Dermatology Unit, Arcispedale Santa Maria Nuova IRCCS, Reggio Emilia, 2Division of Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy Abstract: The outlook for patients with psoriasis has improved significantly...
Saved in:
Main Authors: | Di Lernia V (Author), Bardazzi F (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2016-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tofacitinib citrate for the treatment of refractory, severe chronic actinic dermatitis
by: Matthew D. Vesely, MD, PhD, et al.
Published: (2017) -
Potential role of ixekizumab in the treatment of moderate-to-severe plaque psoriasis
by: Ren V, et al.
Published: (2013) -
Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
by: Gisondi P, et al.
Published: (2016) -
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
by: Näslund-Koch C, et al.
Published: (2020) -
Profile of tildrakizumab-asmn in the treatment of moderate-to-severe plaque psoriasis: evidence to date
by: Beck KM, et al.
Published: (2018)